Cisplatin News and Research RSS Feed - Cisplatin News and Research

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

Necitumumab drug shows minor added benefit in patients with metastatic NSCLC

The monoclonal antibody necitumumab has been approved since February 2016 for the treatment of patients with locally advanced or metastatic epidermal growth factor receptor (EGFR) expressing non-small cell lung cancer (NSCLC) who have not received prior chemotherapy for this condition. [More]
First-line nivolumab promising in advanced NSCLC

First-line nivolumab promising in advanced NSCLC

Phase I results published in the Journal of Clinical Oncology suggest that nivolumab, either given alone or alongside platinum-based doublet chemotherapy, could have a role in the first-line treatment of advanced non-small-cell lung cancer. [More]
Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

Chemoradiotherapy and post-operative chemotherapy provide similar outcomes in gastric cancer patients

Post-operative treatment intensification with chemoradiotherapy does not achieve better outcomes when compared to post-operative chemotherapy in patients with gastric cancer who have already undergone pre-operative chemotherapy, according to phase III data presented at the ESMO 18th World Congress of Gastrointestinal Cancer in Barcelona, Spain. [More]
Study examines role of HOX genes in ovarian cancer resistance

Study examines role of HOX genes in ovarian cancer resistance

A new UK study has identified a gene signature that predicts poor survival from ovarian cancer. The study also identified genes which help the cancer develop resistance to chemotherapy - offering a new route to help tackle the disease. [More]
Cisplatin-based chemotherapy may lead to hearing loss in many testicular cancer survivors

Cisplatin-based chemotherapy may lead to hearing loss in many testicular cancer survivors

Many testicular cancer survivors experience hearing loss after cisplatin-based chemotherapy, according to researchers at Indiana University. [More]
ERCC2 validated as chemotherapy response biomarker in bladder cancer

ERCC2 validated as chemotherapy response biomarker in bladder cancer

Somatic mutations in the helicase-encoding ERCC2 gene are associated with response to neoadjuvant cisplatin-based chemotherapy in patients with muscle-invasive urothelial bladder carcinoma. [More]
Researchers aim to protect kidneys while improving cisplatin's efficacy against cancer

Researchers aim to protect kidneys while improving cisplatin's efficacy against cancer

Cisplatin is a common, powerful chemotherapy agent used for a wide range of cancers such as breast, ovarian and lung, that in a handful of days can also permanently damage or destroy patients' kidneys. [More]
Whole-exome sequencing can help characterize genetic alterations for commonly used bladder cancer cell lines

Whole-exome sequencing can help characterize genetic alterations for commonly used bladder cancer cell lines

Much of basic cancer research is based on studies with cultured cancer cells. However, the usefulness of these studies greatly depends on how accurately these cancer cells grown in a dish represent human tumors. [More]
Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

Drug candidate delivered by plant-virus-based carrier shows promise for triple-negative breast cancer

In a pair of firsts, researchers at Case Western Reserve University and Massachusetts Institute of Technology have shown that the drug candidate phenanthriplatin can be more effective than an approved drug in vivo, and that a plant-virus-based carrier successfully delivers a drug in vivo. [More]
Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Metformin along with chemotherapy/radiation improves outcomes in head and neck cancer patients

Researchers at the University of Cincinnati College of Medicine have found that adding increasing doses of an approved Type 2 diabetes drug, metformin, to a chemotherapy and radiation treatment regimen in head and neck cancer patients is not well tolerated if escalated too quickly, but allowing slower escalation could be beneficial. [More]
Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

Novel drug atezolizumab harnesses immune system to shrink tumors in advanced bladder cancer

A new drug that harnesses the immune system to attack tumors is highly effective against advanced bladder cancer, according to the results of an international clinical trial to be presented June 5 at the annual meeting of the American Society for Clinical Oncology. [More]
Increasing specific microRNA levels can restore chemotherapy sensitivity in pancreatic cancer cells

Increasing specific microRNA levels can restore chemotherapy sensitivity in pancreatic cancer cells

By increasing the level of a specific microRNA (miRNA) molecule, researchers have for the first time restored chemotherapy sensitivity in vitro to a line of human pancreatic cancer cells that had developed resistance to a common treatment drug. [More]
Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

Combination of chemotherapy and immunotherapy may be effective against ovarian cancer

Inside each ovarian tumor, there are good cells and bad cells: The bad cells are fibroblasts. They work to block chemotherapy, which is why nearly every woman with ovarian cancer becomes resistant to treatment. [More]
Action on Hearing Loss funds new study to discover ways of preventing deafness caused by cancer drug

Action on Hearing Loss funds new study to discover ways of preventing deafness caused by cancer drug

A widely used anti-cancer drug, cisplatin, can cause permanent and severe hearing loss, having a devastating impact on the quality of life for cancer survivors. [More]
Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

Effective chemotherapeutic drug may induce permanent hearing loss in Cockayne syndrome individuals

The chemotherapy drug cisplatin can kill cancer, but it can also cause permanent hearing loss. [More]
Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

Scottish women with metastatic carcinoma of cervix could now benefit from Avastin treatment

From today, women in Scotland with an advanced and incurable form of cervical cancer could benefit from the targeted treatment Avastin, which has been given the green light by the Scottish Medicines Consortium (SMC) for routine use on the NHS. [More]
Bayer-new phase 3 liver cancer data

Bayer-new phase 3 liver cancer data

Bayer has announced that a Phase III trial evaluating its oncology compound Stivarga® (regorafenib) tablets for the treatment of patients with unresectable hepatocellular carcinoma (HCC) has met its primary endpoint of a statistically significant improvement in overall survival. The study, called RESORCE, evaluated the efficacy and safety of regorafenib in patients with HCC whose disease has progressed after treatment with sorafenib. The safety and tolerability were generally consistent with the known profile of regorafenib. Detailed efficacy and safety analyses from this study are expected to be presented at an upcoming scientific congress. [More]

Added benefit of crizotinib drug for first-line treatment of advanced bronchial carcinoma not proven

The drug crizotinib (trade name: Xalkori) has been available since 2012 for patients with advanced non-small cell lung cancer (bronchial carcinoma) who have a high activity of the enzyme anaplastic lymphoma kinase (ALK) and have already received another treatment. In November 2015, the approval was extended to first-line treatment. [More]
Fertility 'reassurance' for most chemotherapy-treated female childhood cancer survivors

Fertility 'reassurance' for most chemotherapy-treated female childhood cancer survivors

Both female and male chemotherapy-treated survivors of childhood cancer have an increased risk of impaired fertility, but results suggest that the risk in women is limited to those given specific chemotherapy drugs. [More]
Scientists develop triple-stage 'cluster bomb' system to deliver cisplatin drug through nanoparticles

Scientists develop triple-stage 'cluster bomb' system to deliver cisplatin drug through nanoparticles

Scientists have devised a triple-stage "cluster bomb" system for delivering the chemotherapy drug cisplatin, via tiny nanoparticles designed to break up when they reach a tumor. [More]
Advertisement
Advertisement